NYSE:PFE - Pfizer Stock Price, Price Target & More

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Pfizer announced a quarterly dividend on Thursday, June 28th. Investors of record on Friday, August 3rd will be given a dividend of $0.34 per share on Tuesday, September 4th. This represents a $1.36 dividend on an annualized basis and a yield of 3.61%. The ex-dividend date of this dividend is Thursday, August 2nd. View Pfizer's Dividend History.

Pfizer announced that its board has initiated a stock buyback plan on Tuesday, December 19th 2017, which allows the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company's board of directors believes its stock is undervalued.

Pfizer Inc. (NYSE:PFE) released its earnings results on Tuesday, May, 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.74 by $0.03. The biopharmaceutical company earned $12.91 billion during the quarter, compared to the consensus estimate of $13.14 billion. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The firm's revenue was up 1.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.69 EPS. View Pfizer's Earnings History.

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pfizer.

Pfizer issued an update on its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share (EPS) guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.95. The company issued revenue guidance of $53.5-55.5 billion, compared to the consensus revenue estimate of $54.45 billion.

21 brokerages have issued twelve-month price objectives for Pfizer's stock. Their predictions range from $36.00 to $45.00. On average, they expect Pfizer's share price to reach $40.4167 in the next twelve months. This suggests a possible upside of 7.3% from the stock's current price. View Analyst Ratings for Pfizer.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 2 sell ratings, 9 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Pfizer saw a decrease in short interest in the month of June. As of June 29th, there was short interest totalling 59,174,572 shares, a decrease of 8.5% from the June 15th total of 64,685,349 shares. Based on an average trading volume of 21,034,138 shares, the short-interest ratio is currently 2.8 days. Currently, 1.0% of the company's stock are short sold. View Pfizer's Current Options Chain.

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Media coverage about PFE stock has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pfizer earned a media sentiment score of 0.22 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 45.87 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Pfizer's stock is owned by many different of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.66%), Bank of Montreal Can (0.37%), Hexavest Inc. (0.10%), NN Investment Partners Holdings N.V. (0.09%), Swedbank (0.06%) and Retirement Systems of Alabama (0.05%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

PFE stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Bank of Montreal Can, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Assenagon Asset Management S.A., Retirement Systems of Alabama, Swedbank, KAMES CAPITAL plc and Gateway Investment Advisers LLC. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

PFE stock was bought by a variety of institutional investors in the last quarter, including Jensen Investment Management Inc., Fisher Asset Management LLC, State of Alaska Department of Revenue, Calamos Advisors LLC, IFM Investors Pty Ltd, Pendal Group Ltd, DnB Asset Management AS and Pennsylvania Trust Co. View Insider Buying and Selling for Pfizer.

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PFE stock can currently be purchased for approximately $37.66.

Pfizer has a market capitalization of $222.52 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.